Prosecution Insights
Last updated: November 04, 2026
Application No. 18/707,895

MULTICYCLIC COMPOUNDS

Non-Final OA §103§112
Filed
May 07, 2024
Priority
Nov 13, 2021 — provisional 63/279,094 +7 more
Examiner
VALENROD, YEVGENY
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Atlee Biotech Inc.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
749 granted / 1032 resolved
+12.6% vs TC avg
Strong +25% interview lift
Without
With
+25.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
46 currently pending
Career history
1084
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
38.2%
-1.8% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
21.3%
-18.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1032 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Change of Examiner This application has been reassigned to Examiner Valenrod whose contact information is provided in the conclusion of this document. Election/Restrictions Applicant’s election of Group (I) encompassing claims 1-4, 8, 10-14, 16-17, 21-22, 24-27 and 29 in the reply filed on 5/8/26 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claim 37 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 5/8/26. Election of ALB-23173 as a species for examination is acknowledged. Elected species is free of art A search has failed to uncover art that anticipates or suggests the elected ALB-23173. Search has been expanded to encompass the full scope of compounds I and II. Claims 1-4, 8, 10-14, 16-17, 21-22 and 24 read on the elected subject matter. Claims 25-27 and 29 are withdrawn. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-4, 8, 10-14, 16-17, 21-22 and 24 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for using the compounds of formula I and II with: R1 = unsubstituted Furan R2 = CH2 or O R3 = H or CH3 R4 = OH, benzoyl with optional substituents depicted in claim 1, acetyl, -OCH2OCH3 R7 = H R8 = O Specification does not reasonably provide enablement for using the compounds within the full scope of compound I and II. The specification does not enable any skilled pharmacologist or physician to use the invention commensurate in scope with these claims. There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue." These factors include, but are not limited to: (a) the nature of the invention; (b) the breadth of the claims; (c) the state of the prior art; (d) the amount of direction provided by the inventor; (e) the existence of working examples; (f) the relative skill of those in the art; (g) whether the quantity of experimentation needed to make or use the invention based on the content of the disclosure is "undue"; and (h) the level of predictability in the art (MPEP 2164.01 (a)). a) The nature of the invention is agonism of KOR and treatment of human diseases with Applicants' compounds. This involves physiological activity. The nature of the invention requires an understanding of the KOR receptor, the binding activity of small ligands to that receptor, and the ability of those compounds to agonize KOR. In view of the unpredictability of receptor binding activity and claimed divergent substituents with varied polarity, size, and polarisability, the skilled physician would indeed question the inclusion of diverse substituents commensurate in scope with these claims. Also see the MPEP § 2164.03 for enablement requirements in the structure sensitive arts of pharmacology and medicinal chemistry b) The breadth of claims is the scope of the claimed compounds c) Prior art recognizes Salvinorin A and some of it’s derivatives as KOR agonist (Crowley et al. Journal of Medicinal Chemistry, 2016, 59, 11027-11038). d) Art provides examples 3.1 -3.3 where 8 of the claimed compounds are tested in the KOR assay. All of the tested compounds have an unsubstituted 2-furyl as R1; H as R7; CO2Me as R9, and O as R8. With regards R4 the only exemplified groups are acetyl, OH, OCH2OCH3, and 3-phenyl propenyl group. The examples also indicate great variability in efficacy as reported by EC50 based on nature of R4. For example ALB-2311360 received efficacy score of “D”, which is a 1000 to 10000 times less effective than SalA. e) The state of the art and applicant’s own examples indicate that there is great variability in efficacy of SalA derivatives. Applicant’s examples are described above. In addition, Crawley also describes changes in R4 substituent having a profound effect on activity (See activity of compound 4 vs compound 1c). The diverse claimed substituents are chemically non-equivalent and there is no basis in the prior art for assuming in the non-predictable art of pharmacology that structurally dissimilar compounds will have such activity, In re Surrey 151 USPQ 724 (compounds actually tested which demonstrated the asserted psychomotor stimulatory and anti-convulsant properties were those having the 3,4-dichlorophenyl substituent at the 2-position on the thiazolidone nucleus not sufficient for enablement of any heterocyclic radical at the same position). In re Fouche, 169 USPQ 429 at 434 (a Markush group including both aliphatic and heterocyclic members not enabled for the use of those compounds within the claim having heterocyclic moieties.) In re CAVALLITO AND GRAY, 127 USPQ 202 (claims covering several hundred thousand possible compounds, of which only thirty are specifically identified in appellants' application, not enabled unless all of the thirty specific compounds disclosed had equal hypotensive potency because that fact would strongly indicate that the potency was derived solely from the basic structural formula common to all of them. A wide variation in such potency would suggest that it was due in part to the added substituents and might be eliminated or even reversed by many of the possible substituents which had not been tried.) f) The artisan using Applicants' invention to treat diseases with the claimed compounds would be a physician with a MD degree and several years of experience. He would be unaware of how to predict a priori how a changing a substituent would affect biological activity. In view of the divergent claimed substituents with varied basicity, steric hindrance, and polarisability, the skilled physician would indeed question the inclusion of such compounds, commensurate in scope with these claims. Physiological activity is well-known to be unpredictable, In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In re Wright, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 496, 20 USPQ2d 1438, 1445 (Fed. Cir. 1991). MPEP 2164.01(a) states, “A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993).” That conclusion is clearly justified here. Thus, undue experimentation will be required to practice Applicants' invention. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-4, 12-14, 21, 22 and 24 is/are rejected under 35 U.S.C. 103 as being unpatentable over Crowley et al. (Journal of Medicinal Chemistry, 2016, 59, 11027-11038) in view of Laev et al (Current Medicinal Chemistry, 2021, 28, 6234-6273). Scope of prior art Crowley teaches compounds 4 and 5 (page 11028, Scheme 1): PNG media_image1.png 156 268 media_image1.png Greyscale Ascertaining the difference Compounds 4 and 5 differ from the claimed compound in that substituent R3 in the claimed compound is H, while in compounds 4 and 5 there is a methyl group in corresponding position. Secondary reference Laev teaches that deletion of C20 methyl group in Salvinorin A resulted in 20-nor-salvorin A (compound 89) which retained the high affinity and selectivity for the KOR. (page 6249, column 1, paragraph 3) PNG media_image2.png 190 312 media_image2.png Greyscale Obviousness A person of ordinary skill in the art, prior to the earliest effective filing date of the current application, would have found it obvious to prepare derivatives of compound 4 and 5 of Crowley where the methyl group is replaced with a hydrogen atom. Laev teaches that methyl for hydrogen substitution is not expected to alter the selectivity or efficacy of the compound with regards to KOR activity. Additionally it is well established that the substitution of methyl for hydrogen on a known compound is not a patentable modification absent unexpected or unobvious results. In re Lincoln, 126 U.S. P.Q. 477, 51 U.S.P.Q. 40 (C.C.P.A. 1942); In re Druey, 319 F.2d 237, 138 U.S.P.Q. 39 (C.C.P.A. 1963); In re Lohr, 317 F.2d 388, 137 U.S.P.Q. 548 (C.C.P.A. 1963): In re Hoehsema, 399 F.2d 269, 158 US.P.Q. 598 (C.C.P.A. 1968); In re Wood, 582 F.2d 638, 199 U.S.P.Q. 137 (C.C.P.A. 1978); In re Hoke, 560 F.2d 436, 195 U.S.P.Q. 148 (C.C.P.A. 1977); Ex parte Fauque, 121 U.S.P.Q. 425 (P.O.B.A. 1954); Ex parte Henkel. 130 U.S.P.Q. 474. (P.O.B.A. 1960). Conclusion Claims 1-4, 8, 10-14, 16-17, 21-22, 24-27, 29 and 37 are pending Claims 25-27, 29 and 37 are withdrawn Claims 1-4, 8, 10-14, 16-17, 21-22 and 24 are rejected Any inquiry concerning this communication or earlier communications from the examiner should be directed to YEVGENY VALENROD whose telephone number is (571)272-9049. The examiner can normally be reached Mon-Fri 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YEVGENY VALENROD/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

May 07, 2024
Application Filed
Sep 17, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778970
SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF
3y 6m to grant Granted Nov 03, 2026
Patent 12778924
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS IN ANIMAL OF FAMILY CANIDAE, COMPRISING ENAVOGLIFLOZIN
2y 11m to grant Granted Nov 03, 2026
Patent 12773402
Use of Chloroquine Compounds for Treatment of Inflammatory Conditions
2y 2m to grant Granted Oct 27, 2026
Patent 12767664
SPIROCYCLIC COMPOUND AS KRAS-G12C INHIBITOR
2y 9m to grant Granted Oct 20, 2026
Patent 12746233
REBAMIPIDE FOR USE IN PREVENTION AND/OR TREATMENT OF ARTERIAL STIFFNESS
4y 7m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
98%
With Interview (+25.0%)
2y 6m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1032 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month